Brief Report on Apellis Pharmaceuticals Stock

Shares of Healthcare sector company Apellis Pharmaceuticals moved -6.1% today, and are now trading at a price of $47.36. The mid-cap stock's daily volume was 2,845,090 compared to its average volume of 1,428,031. The S&P 500 index returned a 1.0% performance.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company is based in Waltham and has 476 full time employees. Its market capitalization is $5,203,206,656.

17 analysts are following Apellis Pharmaceuticals and have set target prices ranging from $40 to $123 per share. On average, they have given the company a rating of buy. At today's prices, APLS is trading -39.01% away from its average analyst target price of $77.65 per share.

Over the last year, APLS's share price has increased by 49.7%, which represents a difference of 69.5% when compared to the S&P 500. The stock's 52 week high is $70 per share whereas its 52 week low is $33.08. Apellis Pharmaceuticals has averaged free cash flows of $-268,975,250.0 over the last four years, with a mean growth rate of -92.7%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.

For a deeper fundamental analysis into Apellis Pharmaceuticals and other market moving stocks, subscribe to our free newsletter today!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.